Specific changes in faecal microbiota are associated with familial Mediterranean fever.


Journal

Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355

Informations de publication

Date de publication:
10 2019
Historique:
received: 18 02 2019
revised: 13 07 2019
accepted: 18 07 2019
pubmed: 5 8 2019
medline: 31 3 2020
entrez: 5 8 2019
Statut: ppublish

Résumé

Familial Mediterranean fever (FMF) can be complicated by AA amyloidosis (AAA), though it remains unclear why only some patients develop amyloidosis. We examined the gut microbiota composition and inflammatory markers in patients with FMF complicated or not by AAA. We analysed the gut microbiota of 34 patients with FMF without AAA, 7 patients with FMF with AAA, 19 patients with AAA of another origin, and 26 controls using 16S ribosomal RNA gene sequencing with the Illumina MiSeq platform. Associations between bacterial taxa and clinical phenotypes were evaluated using multivariate association with linear models statistical method. Blood levels of interleukin (IL)-1β, IL-6, tumour necrosis factor-α and adipokines were assessed by ELISA; indoleamine 2,3-dioxygenase (IDO) activity was determined by high-performance liquid chromatography. Compared with healthy subjects, specific changes in faecal microbiota were observed in FMF and AAA groups. Several operational taxonomic units (OTUs) were associated with FMF. Moreover, two OTUs were over-represented in FMF-related AAA compared with FMF without AAA. Additionally, higher adiponectin levels and IDO activity were observed in FMF-related AAA compared with FMF without AAA (p<0.05). The presence of specific changes in faecal microbiota in FMF and in FMF-related AAA suggests that intestinal microorganisms may play a role in the pathogenesis of these diseases. These findings may offer an opportunity to use techniques for gut microbiota manipulation.

Identifiants

pubmed: 31377728
pii: annrheumdis-2019-215258
doi: 10.1136/annrheumdis-2019-215258
doi:

Substances chimiques

ADIPOQ protein, human 0
Adiponectin 0
Biomarkers 0
Cytokines 0
Inflammation Mediators 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1398-1404

Investigateurs

Serge Amselem (S)
Camille Louvrier (C)
Léa Savey (L)
Joris Galland (J)
Antoine Hankard (A)
Alexandre Cez (A)
Pierre-Antoine Michel (PA)
Bertrand Knebelmann (B)
Alexandre Hertig (A)
Corinne Isnard Bagnis (C)
Xavier Belenfant (X)
Nicolas Martin Silva (N)
David Saadoun (D)
Tristan Legris (T)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None.

Auteurs

Samuel Deshayes (S)

Service de Médecine Interne, Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France.
Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France.

Soraya Fellahi (S)

UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Centre de Recherche Saint-Antoine, IHU ICAN, Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS 938, Paris, France.

Jean-Philippe Bastard (JP)

UF Biomarqueurs Inflammatoires et Métaboliques, Service de Biochimie, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.
Centre de Recherche Saint-Antoine, IHU ICAN, Sorbonne Universités, UPMC Université Paris 06, INSERM UMRS 938, Paris, France.

Jean-Marie Launay (JM)

Service de Biochimie, INSERM UMR S942, Assistance Publique des Hôpitaux de Paris, Hôpital Lariboisière, Paris, France.

Jacques Callebert (J)

Service de Biochimie, INSERM UMR S942, Assistance Publique des Hôpitaux de Paris, Hôpital Lariboisière, Paris, France.

Thibault Fraisse (T)

Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.

David Buob (D)

Service d'Anatomopathologie, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.

Jean-Jacques Boffa (JJ)

INSERM 1155, Sorbonne Université, AP-HP, Hôpital Tenon, F-75020 Paris, France.

Irina Giurgea (I)

Service de Génétique Médicale, Assistance Publique des Hôpitaux de Paris, Hôpital Trousseau, Paris, France.

Charlotte Dupont (C)

INSERM équipe Lipodystrophies génétiques et acquises. Service de biologiede la reproduction-CECOS, Sorbonne Université, Saint Antoine Research Center, AP-HP, Hôpital Tenon, F-75020 Paris, France.

Sarah Jegou (S)

Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France.

Marjolène Straube (M)

Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France.

Alexandre Karras (A)

Service de Néphrologie, Assistance Publique des Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Achille Aouba (A)

Service de Médecine Interne, Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France.

Gilles Grateau (G)

Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France.

Harry Sokol (H)

Service de Gastroentérologie, Centre de Recherche Saint-Antoine, CRSA, Sorbonne Université, Inserm, AP-HP, Hôpital Saint-Antoine, F-75012 Paris, France harry.sokol@gmail.com sophie.georgin-lavialle@aphp.fr.
MICALIS Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.
Service de Gastroentérologie, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France.

Sophie Georgin-Lavialle (S)

Service de Médecine Interne, Centre de référence des maladies auto-inflammatoires et des amyloses inflammatoires (CEREMAIA), Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Paris, France harry.sokol@gmail.com sophie.georgin-lavialle@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH